免疫性血小板减少症临床试验招募信息（全球在招）
这里汇总了全球正在招募患者的 免疫性血小板减少症（国际通用名 immune thrombocytopenia）新药临床试验，包含试验分期、招募状态、开展国家和研究团队联系方式，全部以中文呈现。数据实时来自全球最大的临床试验注册库 ClinicalTrials.gov。本页同时覆盖ITP、血小板减少、紫癜等说法。
正在招募的免疫性血小板减少症新药试验
A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia
I 期 / II 期招募中美国中国Denmark法国NCT06721013A Real-world Study of Treatment Patterns and Outcomes in Primary Immune Thrombocytopenia Patients Treated With Eltrombopag
不适用招募中SwitzerlandNCT07587723Safety and Efficacy of PRG-1801 in Recurrent/Refractory Primary Immune Thrombocytopenia (ITP)
早期 I 期招募中中国NCT06519565High-Dose Dexamethasone Combined With Orelabrutinib Versus High-Dose Dexamethasone Combined With Placebo in Adult Patients With Newly Diagnosed Primary Immune Thrombocytopenia
III 期招募中中国NCT07559331A Phase 1/2 Study of ESG206 in Patients With Primary Immune Thrombocytopenia
I 期 / II 期招募中中国NCT06853444Avatrombopag in the Treatment of Adult Immune Thrombocytopenia With Autoantibodies
II 期招募中中国NCT04993885A Clinical Study on the Efficacy and Safety of Herombopag in the Treatment of Senile Primary ITP
II 期招募中中国NCT06838949AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion
II 期招募中美国NCT04099966TPO-RA Treatment on Immune Tolerance Induction of ITP Patients With Sustained Platelet Recovery After Treatment Termination
II 期招募中中国NCT06478537Study of PN20 in Adult Patients With Primary Immune Thrombocytopenia (ITP)
I 期招募中中国NCT06880081The Investigate Efficacy and Safety Evaluation of Bortezomib in Patients With Relapsed/Refractory Immune Thrombocytopenia
II 期招募中South KoreaNCT05599880National Registry of Rare Kidney Diseases
不适用招募中英国NCT06065852
免疫性血小板减少症试验不在中国大陆，还能参加吗？
可以尝试四条现实路径：查找国内同类试验、申请同情用药与扩展准入、赴境外研究中心入组、直接写信给申办方申请在华开展。本站提供中英文对照的咨询信模板，患者和家属填写基本情况即可生成。